- Nachrichtendetail
-
11.07.2024 06:58:44 - dpa-AFX: EQS-News: DocMorris with accelerated and significant eRx growth in new customers, market share and revenue (english)
DocMorris with accelerated and significant eRx growth in new customers,
market share and revenue
DocMorris AG / Key word(s): Quarterly / Interim Statement
DocMorris with accelerated and significant eRx growth in new customers,
market share and revenue
11.07.2024 / 06:58 CET/CEST
---------------------------------------------------------------------------
Frauenfeld, 11 July 2024
Press release
DocMorris with accelerated and significant eRx growth in new customers,
market share and revenue
* Tripling of new Rx customers since the introduction of CardLink
* Doubling and continuous increase in eRx market share since January 2024
Since mid-April, the "CardLink" redemption channel has been available
throughout Germany via the DocMorris app. This new service enables users to
redeem e-prescriptions fully digitally. The introduction of CardLink marked
a turning point in the acquisition of new customers. The weekly number of
new Rx customers has tripled since the CardLink launch. The market share of
the e-prescription business is increasing continuously and has doubled in
the first six months of 2024. (1) The promise to deliver eRx orders on the
next working day is being kept, even with increasing volumes, reaching
almost 100 per cent.
DocMorris external revenue (2) grew by 6.4 per cent in local currency in the
second quarter of 2024 compared to the same period of the previous year. In
Group currency, it rose by 5.9 per cent to CHF 267.7 million. As at the end
of June 2024, the number of active customers (3) increased by 300,000 to
10.0 million compared to the previous quarter.
In Germany, external revenue in the second quarter of 2024 rose by 6.7 per
cent in local currency compared to the same period of the previous year. The
hereafter relevant revenue from e-prescriptions increased by over 50 per
cent compared to the previous quarter. The decline in the proportion of
revenues from paper prescriptions via statutory health insurers (GKV) from
previously over 90 per cent to just under 20 per cent, still had a negative
effect in the second quarter. Overall, this led to a significant increase in
Rx revenue in local currency of 17 per cent (20 per cent in Group currency)
compared to the previous quarter and year-on-year still led to a slight
decline of 3.7 per cent. Sales of over-the-counter (OTC) medicines increased
by 7.9 per cent in local currency in the second quarter compared to the
prior year period.
In Spain and France, an inflection point was achieved in the second quarter
with a return to revenue growth of 3.2 per cent in local currency.
The indicative revenue and EBITDA outlook from 20 March 2024 remains in
place. As announced previously, a specified outlook will be published with
the release of half-year results on 20 August.
The financial figures communicated in this press release are preliminary.
The detailed half-year report will be published on 20 August.
Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10
Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1
Agenda
DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online
pharmacy, marketplace and professional healthcare with strong brands in
Germany and other European countries. Deliveries are mainly from the highly
automated logistics centre in Heerlen, the Netherlands, with a capacity of
over 27 million parcels per year. In Spain and France, the company operates
the leading marketplace for health and personal care products in Southern
Europe. With its business model, DocMorris offers its patients, customers
and partners a broad range of products and services. In doing so, DocMorris
is pursuing its vision of creating a digital health ecosystem for everyone
to manage their health in one click. The company was renamed from Zur Rose
Group AG to DocMorris AG in May 2023 after the Swiss business was sold to
Migros/Medbase. Excluding the Swiss business, about 1,600 employees in
Germany, the Netherlands, Spain, France and Switzerland generated an
external revenue of CHF 1,038 million serving currently 10 million active
customers. The shares of DocMorris AG are listed on the SIX Swiss Exchange
(securities number 4261528, ISIN CH0042615283, ticker DOCM). For further
information, please visit corporate.docmorris.com.
(1) DocMorris share of redeemed e-prescriptions compared to the total number
of redeemed e-prescriptions according to Gematik in June.
(2) External revenue consists of the consolidated revenue of DocMorris plus
online revenues of pharmacies supplied by DocMorris, less the consolidated
revenue from supplying them.
(3) Customers supplied by DocMorris, either directly or through its
partners.
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
End of News EQS News Service
---------------------------------------------------------------------------
1943693 11.07.2024 CET/CEST
market share and revenue
DocMorris AG / Key word(s): Quarterly / Interim Statement
DocMorris with accelerated and significant eRx growth in new customers,
market share and revenue
11.07.2024 / 06:58 CET/CEST
---------------------------------------------------------------------------
Frauenfeld, 11 July 2024
Press release
DocMorris with accelerated and significant eRx growth in new customers,
market share and revenue
* Tripling of new Rx customers since the introduction of CardLink
* Doubling and continuous increase in eRx market share since January 2024
* 17 per cent revenue growth of prescription medicines (Rx) compared to
the previous quarter
Since mid-April, the "CardLink" redemption channel has been available
throughout Germany via the DocMorris app. This new service enables users to
redeem e-prescriptions fully digitally. The introduction of CardLink marked
a turning point in the acquisition of new customers. The weekly number of
new Rx customers has tripled since the CardLink launch. The market share of
the e-prescription business is increasing continuously and has doubled in
the first six months of 2024. (1) The promise to deliver eRx orders on the
next working day is being kept, even with increasing volumes, reaching
almost 100 per cent.
DocMorris external revenue (2) grew by 6.4 per cent in local currency in the
second quarter of 2024 compared to the same period of the previous year. In
Group currency, it rose by 5.9 per cent to CHF 267.7 million. As at the end
of June 2024, the number of active customers (3) increased by 300,000 to
10.0 million compared to the previous quarter.
In Germany, external revenue in the second quarter of 2024 rose by 6.7 per
cent in local currency compared to the same period of the previous year. The
hereafter relevant revenue from e-prescriptions increased by over 50 per
cent compared to the previous quarter. The decline in the proportion of
revenues from paper prescriptions via statutory health insurers (GKV) from
previously over 90 per cent to just under 20 per cent, still had a negative
effect in the second quarter. Overall, this led to a significant increase in
Rx revenue in local currency of 17 per cent (20 per cent in Group currency)
compared to the previous quarter and year-on-year still led to a slight
decline of 3.7 per cent. Sales of over-the-counter (OTC) medicines increased
by 7.9 per cent in local currency in the second quarter compared to the
prior year period.
In Spain and France, an inflection point was achieved in the second quarter
with a return to revenue growth of 3.2 per cent in local currency.
The indicative revenue and EBITDA outlook from 20 March 2024 remains in
place. As announced previously, a specified outlook will be published with
the release of half-year results on 20 August.
Revenue, in CHF million (unaudited, 1.4.-30.6.2- 1.4.-30.6.2- Chan- preliminary) 024 023 ge
Continuing operations (excl. Swiss business) DocMorris external revenue 267.7 252.7 5.9% DocMorris external revenue in local 269 253 6.4% currency DocMorris 250.5 235.5 6.4% DocMorris in local currency 252 236 6.9%
Markets
Germany external revenue 250.6 236.1 6.2%
Germany external revenue in local 257.3 241.2 6.7%
currency
Germany external revenue Rx 42.6 44.5 -4.4-
%
Germany external revenue Rx in local -3.7-
currency %
Germany external revenue OTC 204.0 189.9 7.4%
Germany external revenue OTC in local 7.9%
currency
Germany 233.4 218.9 6.6%
Germany in local currency 239.7 223.6 7.2%
Europe 17.0 16.6 2.5%
Europe in local currency 17 17 3.2%
Revenue, in CHF million (unaudited, 1.1.-30.6.2- 1.1.-30.6.2- Chan-
preliminary) 024 023 ge
Continuing operations (excl. Swiss business) DocMorris external revenue 530.0 501.4 5.7% DocMorris external revenue in local 543 501 8.4% currency DocMorris 496.4 463.0 7.2% DocMorris in local currency 509 463 9.9%
Markets
Germany external revenue 497.7 468.5 6.2%
Germany external revenue in local 518 475 8.9%
currency
Germany external revenue Rx 78.1 89.5 -12.-
8%
Germany external revenue Rx in local -10.-
currency 6%
Germany external revenue OTC 412.1 375.7 9.7%
Germany external revenue OTC in local 12.5-
currency %
Germany 464.0 430.0 7.9%
Germany in local currency 483 436 10.6-
%
Europe 32.4 32.9 -1.7-
%
Europe in local currency 33 33 0.7%
The financial figures communicated in this press release are preliminary.
The detailed half-year report will be published on 20 August.
Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10
Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1
Agenda
20 August 2024 Half-year results (conference call/webcast)
2024
15 October Q3/2024 Trading update
2024
21 January Sales 2024
2025
13 March 2024 Full-year results and outlook 2025 (conference
2025 call/webcast)
17 April Q1/2025 Trading Update
2025
8 May 2025 Annual General Meeting, Zurich
19 August 2025 Half-year results (conference call/webcast)
2025
16 October Q3/2025 Trading Update
2025
DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online
pharmacy, marketplace and professional healthcare with strong brands in
Germany and other European countries. Deliveries are mainly from the highly
automated logistics centre in Heerlen, the Netherlands, with a capacity of
over 27 million parcels per year. In Spain and France, the company operates
the leading marketplace for health and personal care products in Southern
Europe. With its business model, DocMorris offers its patients, customers
and partners a broad range of products and services. In doing so, DocMorris
is pursuing its vision of creating a digital health ecosystem for everyone
to manage their health in one click. The company was renamed from Zur Rose
Group AG to DocMorris AG in May 2023 after the Swiss business was sold to
Migros/Medbase. Excluding the Swiss business, about 1,600 employees in
Germany, the Netherlands, Spain, France and Switzerland generated an
external revenue of CHF 1,038 million serving currently 10 million active
customers. The shares of DocMorris AG are listed on the SIX Swiss Exchange
(securities number 4261528, ISIN CH0042615283, ticker DOCM). For further
information, please visit corporate.docmorris.com.
(1) DocMorris share of redeemed e-prescriptions compared to the total number
of redeemed e-prescriptions according to Gematik in June.
(2) External revenue consists of the consolidated revenue of DocMorris plus
online revenues of pharmacies supplied by DocMorris, less the consolidated
revenue from supplying them.
(3) Customers supplied by DocMorris, either directly or through its
partners.
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1943693
End of News EQS News Service
---------------------------------------------------------------------------
1943693 11.07.2024 CET/CEST
